Robin Shane Readnour bought $106k of ANTX
director at AN2 Therapeutics, Inc.. 75,000 shares at an average of $1.41, traded Nov 26, 2024, filed Nov 27, 2024.
Score components
- +15RoleDirector
- +10Trade size$106k at market
- +3Relative to holdingsHoldings up 15%
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +5.1%, 3m -17.5%, 6m -16.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-131660, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 26, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +12,500 | $1.39 | $17k | 527,288 | Nov 27, 2024 |
| Nov 26, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +12,500 | $1.39 | $17k | 597,573 | Nov 27, 2024 |
| Nov 27, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +25,000 | $1.42 | $35k | 552,288 | Nov 27, 2024 |
| Nov 27, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +25,000 | $1.42 | $35k | 622,573 | Nov 27, 2024 |
Related signals
Other insiders at AN2 Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | AN2 Therapeutics, Inc. | Robin Shane Readnour director | $6,675 1,108 shares | -0% | |
| 13Weak | AN2 Therapeutics, Inc. | Robin Shane Readnour director | $97k 16,119 shares | -3% | |
| 23Weak | AN2 Therapeutics, Inc. | Sarah Joanne Williams Principal Accounting Officer | $1,504 272 shares | -0% | |
| 21Weak | ANTXbuy AN2 Therapeutics, Inc. | Margaret M FitzPatrick director | $12k 2,098 shares | +24% | |
| 7Weak | AN2 Therapeutics, Inc. | Robin Shane Readnour director | $213k 35,402 shares | -6% | |
| 15Weak | ANTXsell AN2 Therapeutics, Inc. | Joshua M Eizen See Remarks | $25k 5,945 shares | -3% | |
| 15Weak | ANTXsell AN2 Therapeutics, Inc. | Sarah Joanne Williams Principal Accounting Officer | $1,174 265 shares | -0% | |
| 15Weak | ANTXsell AN2 Therapeutics, Inc. | Sarah Joanne Williams Principal Accounting Officer | $347 327 shares | -0% | |
| 35Weak | AN2 Therapeutics, Inc. | Joshua M Eizen See Remarks | $25k 24,854 shares | -14% | |
| 35Weak | AN2 Therapeutics, Inc. | Sanjay Chanda Chief Development Officer | $9,332 9,251 shares | -11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.